JP2023551712A5 - - Google Patents
Info
- Publication number
- JP2023551712A5 JP2023551712A5 JP2023533382A JP2023533382A JP2023551712A5 JP 2023551712 A5 JP2023551712 A5 JP 2023551712A5 JP 2023533382 A JP2023533382 A JP 2023533382A JP 2023533382 A JP2023533382 A JP 2023533382A JP 2023551712 A5 JP2023551712 A5 JP 2023551712A5
- Authority
- JP
- Japan
- Prior art keywords
- relative humidity
- api
- stable oral
- weight
- oral formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0166051 | 2020-12-01 | ||
| KR20200166051 | 2020-12-01 | ||
| PCT/KR2021/017842 WO2022119269A1 (ko) | 2020-12-01 | 2021-11-30 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023551712A JP2023551712A (ja) | 2023-12-12 |
| JP2023551712A5 true JP2023551712A5 (cg-RX-API-DMAC7.html) | 2025-03-21 |
| JP7678106B2 JP7678106B2 (ja) | 2025-05-15 |
Family
ID=81854222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533382A Active JP7678106B2 (ja) | 2020-12-01 | 2021-11-30 | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む安定した経口用製剤 |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI901895B (zh) * | 2021-06-15 | 2025-10-21 | 南韓商Lg化學股份有限公司 | 一種包含1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸的醫藥組成物 |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005538102A (ja) * | 2002-07-31 | 2005-12-15 | ファルマシア・コーポレーション | 低下された架橋を示すゼラチンカプセル |
| WO2006078948A2 (en) * | 2005-01-21 | 2006-07-27 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of zonisamide and methods for their manufacture |
| CN101679251B (zh) * | 2007-04-11 | 2013-10-02 | 橘生药品工业株式会社 | (氮杂)吲哚衍生物及其医药用途 |
| TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Lg生命科學有限公司 | 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法 |
| WO2020109319A1 (en) * | 2018-11-27 | 2020-06-04 | Zaklady Farmaceutyczne Polpharma S.A | Pharmaceutical composition comprising ramipril and indapamide |
| CA3194595A1 (en) * | 2020-11-04 | 2022-05-12 | Seok Ju Lee | Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same |
| PE20230850A1 (es) * | 2020-12-01 | 2023-05-23 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion |
| PE20240764A1 (es) * | 2021-04-16 | 2024-04-17 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico |
-
2021
- 2021-11-30 KR KR1020210167928A patent/KR20220077091A/ko active Pending
- 2021-11-30 WO PCT/KR2021/017842 patent/WO2022119269A1/ko not_active Ceased
- 2021-11-30 JP JP2023533382A patent/JP7678106B2/ja active Active
- 2021-11-30 PE PE2023001504A patent/PE20240222A1/es unknown
- 2021-11-30 TW TW114111064A patent/TW202600130A/zh unknown
- 2021-11-30 MX MX2023005459A patent/MX2023005459A/es unknown
- 2021-11-30 EP EP21900957.8A patent/EP4257123A4/en not_active Withdrawn
- 2021-11-30 TW TW112117938A patent/TWI896975B/zh active
- 2021-11-30 AU AU2021390901A patent/AU2021390901B9/en not_active Ceased
- 2021-11-30 AR ARP210103303A patent/AR124178A1/es unknown
- 2021-11-30 TW TW110144682A patent/TWI840721B/zh active
- 2021-11-30 CN CN202180078624.3A patent/CN116528852B/zh active Active
- 2021-11-30 CA CA3197405A patent/CA3197405A1/en active Pending
- 2021-11-30 US US18/255,212 patent/US20240000751A1/en not_active Abandoned
-
2023
- 2023-04-27 CL CL2023001215A patent/CL2023001215A1/es unknown
- 2023-05-10 ZA ZA2023/05156A patent/ZA202305156B/en unknown
- 2023-06-23 CO CONC2023/0008265A patent/CO2023008265A2/es unknown
-
2024
- 2024-10-16 AU AU2024227367A patent/AU2024227367A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512117A5 (cg-RX-API-DMAC7.html) | ||
| IL275982B1 (en) | Pharmaceutical compositions for treating cystic fibrosis | |
| US6340695B1 (en) | Rapid onset formulation | |
| CA2483199A1 (en) | High drug load tablet of imatinib | |
| US20130344150A1 (en) | Direct compression tablets of otilonium | |
| JP2016537347A5 (cg-RX-API-DMAC7.html) | ||
| US20160184268A1 (en) | Compositions of eltrombopag | |
| JP2020511419A5 (cg-RX-API-DMAC7.html) | ||
| JP2007503414A5 (cg-RX-API-DMAC7.html) | ||
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| JP2019523258A (ja) | エソメプラゾール、又は薬学的に許容可能なその塩を含むpH依存性薬物放出特性が改善した剤形 | |
| JP2022044699A5 (cg-RX-API-DMAC7.html) | ||
| JP2023536667A5 (cg-RX-API-DMAC7.html) | ||
| JP2023544327A5 (cg-RX-API-DMAC7.html) | ||
| JP2023548855A5 (cg-RX-API-DMAC7.html) | ||
| US20210060019A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
| US20240000751A1 (en) | Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| US9561242B2 (en) | Doxycycline composition | |
| EP4268806A1 (en) | A tablet comprising sacubitril and valsartan processed with dry granulation | |
| WO2011161689A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| JP2024525954A5 (cg-RX-API-DMAC7.html) | ||
| WO2023211412A1 (en) | A tablet comprising sacubitril and valsartan processed with dry granulation | |
| JP2018184381A (ja) | エゼチミブ含有錠剤およびその製法 | |
| US20060020040A1 (en) | Bupropion hydrochloride solid dosage forms | |
| RU2020115172A (ru) | Фармацевтическая композиция, содержащая хинолиновое производное |